Krystal Biotech Inc (KRYS.OQ)
22 Jun 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103
- BRIEF-Krystal Biotech Q1 Loss Per Share $0.21
- BRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
- BRIEF-Krystal Biotech’S Kb103 Receives Orphan Medicinal Product Designation In Europe For Dystrophic Epidermolysis Bullosa
- BRIEF-Krystal Submits Investigational New Drug (Ind) Application For KB103